Are Weight Loss Jabs Affecting Your Patients’ Vision? Post Date : September 23, 2025 General Health 2 minutes read Have you noticed an increasing number of patients walking into your practice who are taking weight loss medications like Ozempic or Mounjaro? You’re not alone. The rise in popularity of these “weight loss jabs” has prompted questions from optometrists across the country, who are now asking: what are the ocular effects of these powerful new medications? One optometrist recently reached out to us, voicing a concern that many of you share: ‘In practice, we are increasingly seeing patients who are taking the newer weight loss medications, Ozempic and Mounjaro, for example. Could CHEC inform us in more detail the ocular effects of these medications?’ At CHEC, we’re proud to partner with optometrists and we’re always here to help with any queries you may have. This is exactly why we’re hosting our national webinar, to provide the answers and support you need to navigate these new challenges. Your patients are losing weight and managing their blood sugar, but at what potential cost to their vision? From fluctuating vision and blurred eyesight to more serious complications, the link between these drugs and eye health is an emerging and vital topic for every optometrist. The question isn’t just what these medications do to a patient’s eyes now, but what happens six months, a year, or even after they stop taking them? The answers aren’t always straightforward. We’ll delve into the studies and data, examining topics such as: The potential association with other conditions, such as wet AMD and NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy).The risk of blurred vision and how it can affect patients, especially at the beginning of their treatment.The potential for worsening diabetic retinopathy, a phenomenon known as “early worsening” that can occur with rapid improvements in blood sugar control.The link to more serious retinal issues, including an increased incidence of vitreous haemorrhage and retinal detachments. If you’re seeing these patients and have been searching for answers, this is the webinar for you. Join Ophthalmologist Dr Moemen Elnawawy as he explores “GLP1 RAs: The Good, The Bad and Why We Should Care”. Don’t miss this essential session that will equip you with the knowledge to better serve your patients and understand the broader impact of these medications on eye health. Find out more and register your place at our national webinar. Spaces are limited!